Plus Therapeutics Shares Jump As First Patient Treated In Latest Cohort Of Brain Tumor Trial

Plus Therapeutics Inc PSTV has announced that the first patient in the eighth cohort of Phase 1 dose-escalation ReSPECT-GBM trial for recurrent glioblastoma (rGBM) has been treated.
The present cohort implements a 40% increase in volume (12.3 milliliters) and total radioactivity (31.2 millicuries) from the previous cohort.
"The ReSPECT-GBM Phase 1 clinical trial is progressing on schedule and with an acceptable safety profile," said Marc H. Hedrick, President & CEO.
The Company will provide an update by the end of 2021.
22 patients across eight dosing cohorts have been treated in the ReSPECT trial to date.
Thus far, no treatment-emergent dose-limiting toxicities have been observed, despite absorbed radiation doses to the tumor of up to 740 Gray.
Price Action: PSTV shares are up 9.48% at $2.54 during the premarket session on the last check Thursday.